HLA-DRB1 and neoplasm: We examined cytokine secretion profiles (IL-2, IL-4, IL-6, and IFNG) (21–24) from activated T cells (CD69, IL-2RA, CD38, and HLA-DRB1) (25) to evaluate T-cell activation in the CM tumor microenvironment, revealing consistently low expression levels.